These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30413829)

  • 21. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
    Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
    Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
    Muscelli E; Astiarraga B; Barsotti E; Mari A; Schliess F; Nosek L; Heise T; Broedl UC; Woerle HJ; Ferrannini E
    Diabetologia; 2016 Apr; 59(4):700-8. PubMed ID: 26704626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad.
    Clement Y; Singh S; Motilal S; Maharaj R; Nunez-Smith M
    Ethn Dis; 2020; 30(Suppl 1):211-216. PubMed ID: 32269463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
    Charpentier G; Fleury F; Kabir M; Vaur L; Halimi S
    Diabet Med; 2001 Oct; 18(10):828-34. PubMed ID: 11678974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy.
    Magnussen LV; Glintborg D; Hermann P; Hougaard DM; Højlund K; Andersen M
    Diabetes Obes Metab; 2016 Oct; 18(10):980-9. PubMed ID: 27265844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.
    Zeng W; Guo Y; Chen P; Liu Z; Chen D; Han C
    J Diabetes Investig; 2016 Sep; 7(5):764-8. PubMed ID: 27181593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus.
    Corbould A; Swinton F; Radford A; Campbell J; McBeath S; Dennis A
    Aust N Z J Obstet Gynaecol; 2013 Apr; 53(2):125-9. PubMed ID: 23205962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
    Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
    Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
    Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
    Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.
    Garber AJ; Larsen J; Schneider SH; Piper BA; Henry D;
    Diabetes Obes Metab; 2002 May; 4(3):201-8. PubMed ID: 12047399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
    Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
    Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transporters Involved in Metformin Pharmacokinetics and Treatment Response.
    Liang X; Giacomini KM
    J Pharm Sci; 2017 Sep; 106(9):2245-2250. PubMed ID: 28495567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
    Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
    Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2].
    Vuković M; Lapcević M; Kalezić N; Gvozdenović BS
    Srp Arh Celok Lek; 2007; 135(7-8):447-52. PubMed ID: 17929538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical activity modifies the effect of SNPs in the SLC2A2 (GLUT2) and ABCC8 (SUR1) genes on the risk of developing type 2 diabetes.
    Kilpeläinen TO; Lakka TA; Laaksonen DE; Laukkanen O; Lindström J; Eriksson JG; Valle TT; Hämäläinen H; Aunola S; Ilanne-Parikka P; Keinänen-Kiukaanniemi S; Tuomilehto J; Uusitupa M; Laakso M;
    Physiol Genomics; 2007 Oct; 31(2):264-72. PubMed ID: 17636114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
    Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
    Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.